Krilogy Financial LLC Buys New Shares in Natera, Inc. $NTRA

Krilogy Financial LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 8,219 shares of the medical research company’s stock, valued at approximately $1,323,000.

Other institutional investors have also recently made changes to their positions in the company. Sound Income Strategies LLC lifted its position in shares of Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after buying an additional 110 shares in the last quarter. Quent Capital LLC purchased a new stake in Natera in the 3rd quarter worth approximately $46,000. Hilltop National Bank raised its stake in Natera by 59.8% during the 3rd quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock worth $50,000 after acquiring an additional 116 shares during the period. N.E.W. Advisory Services LLC raised its stake in Natera by 256.8% during the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after acquiring an additional 226 shares during the period. Finally, AXS Investments LLC purchased a new position in Natera during the third quarter valued at approximately $69,000. Institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In other news, CFO Michael Burkes Brophy sold 6,939 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the sale, the chief financial officer directly owned 52,120 shares of the company’s stock, valued at $11,874,499.60. This represents a 11.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Solomon Moshkevich sold 1,639 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total value of $378,232.03. Following the transaction, the insider owned 137,847 shares of the company’s stock, valued at $31,810,952.19. This represents a 1.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 455,899 shares of company stock valued at $106,475,440 over the last three months. Corporate insiders own 5.63% of the company’s stock.

Natera Stock Down 2.2%

Shares of NTRA stock opened at $207.84 on Friday. The company’s fifty day simple moving average is $231.14 and its two-hundred day simple moving average is $198.16. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The stock has a market cap of $28.75 billion, a P/E ratio of -90.76 and a beta of 1.64.

Analyst Ratings Changes

NTRA has been the subject of a number of analyst reports. Barclays increased their price objective on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research note on Monday, January 12th. Finally, Evercore increased their target price on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.